 |
18 Diseases |  |
22 Trials |
|
22 Trials |  |
2501 News |  |
| «12...910111213141516171819...2122» |
- | Daklinza (daclatasvir) / BMS
Journal: An intervention to improve HCV testing, linkage to care, and treatment among people who use drugs in Tehran, Iran: The ENHANCE study. (Pubmed Central) - May 23, 2020
Following on-site HCV testing and linkage to care, HCV treatment uptake was extremely high among PWUD, apart from the homeless reception population. This intervention could be explored in other settings globally to enhance HCV scale-up and elimination efforts.
- | Veklury (remdesivir) / Gilead
Journal: Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. (Pubmed Central) - May 23, 2020
Furthermore, we provide evidence for the target specificity of RDV, as RDV-TP was less efficiently incorporated by the distantly related Lassa virus RdRp, and termination of RNA synthesis was not observed. These results collectively provide a unifying, refined mechanism of RDV-mediated RNA synthesis inhibition in coronaviruses and define this nucleotide analogue as a direct-acting antiviral (DAA).
- || Clinical, Journal: Successful fourth line treatment of a relapse patient with chronic hepatitis C virus infection genotype 3a using sofosbuvir, glecaprevir/pibrentasvir, and ribavirin: a case report. (Pubmed Central) - May 23, 2020
These results collectively provide a unifying, refined mechanism of RDV-mediated RNA synthesis inhibition in coronaviruses and define this nucleotide analogue as a direct-acting antiviral (DAA). The combination of sofosbuvir, glecaprevir/pibrentasvir and ribavirin could be a rescue therapy after previous relapses on DAA-therapy, especially in patients with relapse after therapy with sofosbuvir, velpatasvir, and voxilaprevir.
- || Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead, Sovaldi (sofosbuvir) / Gilead
Trial completion date, Trial primary completion date: A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials (clinicaltrials.gov) - May 21, 2020
P=N/A, N=500, Enrolling by invitation, Sponsor: Gilead Sciences
The combination of sofosbuvir, glecaprevir/pibrentasvir and ribavirin could be a rescue therapy after previous relapses on DAA-therapy, especially in patients with relapse after therapy with sofosbuvir, velpatasvir, and voxilaprevir. Trial completion date: Sep 2027 --> Nov 2024 | Trial primary completion date: Sep 2027 --> Nov 2024
- | Sovaldi (sofosbuvir) / Gilead
Journal: Major royal-jelly protein 2 and its isoform X1 are two novel safe inhibitors for hepatitis C and B viral entry and replication. (Pubmed Central) - May 19, 2020
The efficiency of these proteins was evaluated in vitro and their safety was examined in vivo in comparison with Sofosbuvir (SOF) drug...The studied proteins maximized their antiviral effect by their safety and superior potency to SOF. Collectively, these outcomes will shed the light on MRJP2 and its isoform X1 as two promising safe-inhibitors for both HCV and HBV.
- || Sovaldi (sofosbuvir) / Gilead
Clinical, Retrospective data, Journal, Real-World Evidence: Sofosbuvir-based regimens in the treatment of patients with chronic hepatitis C virus infection: Real-world efficacy in Thailand. (Pubmed Central) - May 19, 2020
Collectively, these outcomes will shed the light on MRJP2 and its isoform X1 as two promising safe-inhibitors for both HCV and HBV. Sofosbuvir-based regimens in the treatment of patients with chronic HCV infection were highly efficacious with excellent safety and tolerability profiles in a real-world setting; however, further research is required to establish whether or not such a regimen is an adequate treatment for all genotype 6 patients.
- || Copegus (ribavirin) / Bausch Health, Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
Clinical, Journal: Comparing the risk of hypothyroidism in HCV patients treated with different DAA drugs combinations (sofosbuvir + interferon + ribavirin and sofosbuvir + daclatasvir + ribavirin). (Pubmed Central) - May 19, 2020
This study compared the risk of hypothyroidism in two different groups of HCV patients treated with different DAA drugs regimens that were sofosbuvir + pegylated-IFN-α + ribavirin and sofosbuvir + daclatasvir + ribavirin. Our findings highlight the periodic screening of serum thyroid-stimulating hormone and T4 levels in HCV infected patients during the treatment and posttreatment.
- | Sovaldi (sofosbuvir) / Gilead
Journal: Knowledge-based repositioning of the anti-HCV direct antiviral agent Sofosbuvir as SARS-CoV-2 treatment. (Pubmed Central) - May 19, 2020
Indeed, the RNA-dependent RNA-polymerases (RdRp) of the two viruses show high sequence and structural homology, supporting the likelihood of binding the Sofosbuvir molecule with similar efficiency. Such a repositioning would allow the containment of the SARS-CoV-2 pandemic and limit the progression of disease to potentially deadly COVID19.
- | Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
Trial completion date, Combination therapy: MAGELLAN-3: Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study (clinicaltrials.gov) - May 19, 2020
P3, N=50, Enrolling by invitation, Sponsor: AbbVie
Such a repositioning would allow the containment of the SARS-CoV-2 pandemic and limit the progression of disease to potentially deadly COVID19. Trial completion date: Sep 2020 --> Jun 2021
- | Zepatier (grazoprevir/elbasvir) / Merck (MSD), Sovaldi (sofosbuvir) / Gilead
Enrollment closed, Trial completion date, Trial primary completion date: A Direct obserVed therApy vs fortNightly CollEction Study for HCV Treatment - ADVANCE HCV Study (clinicaltrials.gov) - May 17, 2020
P2, N=135, Active, not recruiting, Sponsor: University of Dundee
Trial completion date: Sep 2020 --> Jun 2021 Recruiting --> Active, not recruiting | Trial completion date: Mar 2020 --> Dec 2020 | Trial primary completion date: Feb 2020 --> Jul 2020
- | Sovaldi (sofosbuvir) / Gilead
New P1/2 trial: Sofosbuvir/Ombitasvir/Paritaprevir/ Ritonavir and Ribavirin for Hepatitis C Virus Genotype 4 Patients (clinicaltrials.gov) - May 17, 2020
P1/2, N=113, Completed, Sponsor: Beni-Suef University
- | Daklinza (daclatasvir) / BMS, lopinavir/ritonavir / Generic mfg.
Journal: Minimum costs to manufacture new treatments for COVID-19. (Pubmed Central) - May 16, 2020
Should repurposed drugs demonstrate efficacy against COVID-19, they could be manufactured profitably at very low costs, for much less than current list prices. Estimations for the minimum production costs can strengthen price negotiations and help ensure affordable access to vital treatment for COVID-19 at low prices globally.
- Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
[VIRTUAL] OUTCOME OF DIFFUSE LARGE B-CELL LYMPHOMA ASSOCIATED WITH HEPATITIS C VIRUS IN ELDERLY PATIENTS: RESULTS OF THE PROSPECTIVE 'ELDERLY PROJECT' BY THE FONDAZIONE ITALIANA LINFOMI (FIL) () - May 16, 2020 - Abstract #EHA2020EHA_933;
Studies comparing DLBCL outcomes based on HCV status in Rituximab-era are rare...Twenty HCV+ patients were treated by DAAs, mainly (n=14, 70%) with sofosbuvir-based regimens, concurrently (n=3, 15%) or subsequently (n=17, 85%) to I-CT...The antiviral therapy with DAAs appears to be a feasible strategy also in this elderly population. The survival of HCV-eradicated cases was excellent, suggesting a possible role in reducing the risk of relapse by eliminating the viral trigger.
- Copegus (ribavirin) / Bausch Health, Sovaldi (sofosbuvir) / Gilead
The effectiveness of different modes of anti‐viral therapy in patients with hepatitis C‐associated (HCV) lymphoma marginal zone (LMZ) () - May 14, 2020 - Abstract #BSH2020BSH_333;
The use of AVT, consisting of interferon (IFN) and ribavirin (RBV) and the new anti‐viral drugs direct action (DAA), at any time during the life of these patients (pts) can cause a high level so anti‐viral anti‐tumour responses...Depending on the treatment the patients were divided into two groups (G): 28(61%) patients received treatment with anti‐viral regime on the basis of IFN (G1), 18 (39%) patients (G2) receive direct anti‐viral drugs (a regimen based on sofosbuvir)...Thus, the duration of DAA therapy should be at least 9 months. Perhaps the combination of these two regimens will increase the effectiveness of treatment for hepatitis C‐associated LMZ
- || Daklinza (daclatasvir) / BMS
Clinical, Journal: HBV reactivation during direct-acting antiviral therapy in hepatitis B and C coinfected patients undergoing haemodialysis. (Pubmed Central) - May 13, 2020
A significant proportion of HBV/HCV co-infected patients undergoing hemodialysis developed HBV reactivation after DAA therapy. The risk of HBV reactivation was greater in HBsAg(+) patients than in those patients who were HBsAg(-) but anti-HBc(+) or HBV DNA(+).
- | Daklinza (daclatasvir) / BMS
Journal: Hepatitis C Virus (HCV) Clearance After Treatment With Direct-Acting Antivirals in Human Immunodeficiency Virus (HIV)-HCV Coinfection Modulates Systemic Immune Activation and HIV Transcription on Antiretroviral Therapy. (Pubmed Central) - May 12, 2020
Elimination of HCV in HIV/HCV-coinfected individuals alters immune function and the transcriptional activity of latently infected cells. This report provides insights into the effects of HCV coinfection in HIV persistence and regards coinfected subjects as a population in which HIV remission might prove to be more challenging.
- || Sovaldi (sofosbuvir) / Gilead, ledipasvir/sofosbuvir / Generic mfg.
Clinical, Journal: Efficacy and safety of new direct-acting antivirals in kidney transplant recipients with chronic hepatitis C: a single-center study. (Pubmed Central) - May 10, 2020
The DGFRs in the 1 period and 2 period did not differ significantly between Group 1 and Group 2 patients. In this real-world study of KT recipients with CHC, the high efficacy and clinically acceptable tolerability of DAAs were confirmed.
- || Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
Clinical, Journal: HEPATITIS C TREATMENT OF RENAL TRANSPLANT AND CHRONIC KIDNEY DISEASE PATIENTS: EFFICACY AND SAFETY OF DIRECT-ACTING ANTIVIRAL REGIMENS CONTAINING SOFOSBUVIR. (Pubmed Central) - May 6, 2020
The combination with ribavirin increased the risk of anemia and the administration of escalating doses seems to be useful in patients with GFR <60 mL/min. In patients with GFR <30 mL/min, SOF had no significant renal impact, with serum creatinine returning to levels close to baseline after treatment.
- || Sovaldi (sofosbuvir) / Gilead
Universal access to medicines = no obstacle from IP rights. Health is not a monopoly game, let' she not repeat the Sovaldi disgraceful scandal and make full use of already available legal tools @SKyriakidesEU (Twitter) - May 6, 2020
- | Sovaldi (sofosbuvir) / Gilead, ledipasvir/sofosbuvir / Generic mfg.
@US_FDA GILEAD has track record of 100 deaths in Sovaldi and Harvoni in Georgia - FDA permission to test is criminal intent to humanity of ppl in US refer @dgaytandzhieva @va_shiva (Twitter) - May 5, 2020
- Sovaldi (sofosbuvir) / Gilead
SUSTAINED VIROLOGIC RESPONSE (SVR) TO DAA TREATMENT RESULTS IN A HIGH AND DURABLE RATE OF BOTH ALT AND AST LOWER THAN 30 (MALES)/19 (FEMALES) IU/L IN HCV-INFECTED PATIENTS () - May 4, 2020 - Abstract #DDW2020DDW_6358;
At pre-Rx, only 10.9%, 8.5%, and 5.4% had ALT, AST, or ALT/AST < 30 (M), 19 (F) IU/L, and that increased to 77.3%, 60.2%, and 58.6% at post-Rx wk 48, respectively. Post-Rx wk 48 ALT/AST < 30 (M)/19 (F) IU/L was independently and significantly associated with male gender, both ALT/AST < 30 (M)/19 (F) IU/L at Rx wk 4, and Child score < 6
- Sovaldi (sofosbuvir) / Gilead
DEVELOPMENT OF A LONG-ACTING DIRECT-ACTING ANTIVIRAL SYSTEM FOR HEPATITIS C VIRUS TREATMENT IN A SWINE MODEL () - May 4, 2020 - Abstract #DDW2020DDW_6353;
Tunable release kinetics of DAAs was enabled for one month with drug-polymer pills in vitro, and the LA-DAAS safely and successfully provided month-long release of sofosbuvir in vivo. The LA-DAA system can provide a cost-effective and patient-centric method for HCV treatment, including in high-risk populations who are currently undertreated
- CHARACTERIZATION OF PATIENTS WITH CHRONIC HEPATITIS C (C-HCV) ATTENDED AT A HEPATOLOGY CLINIC OF A COMMUNITY HOSPITAL IN NORTH BROOKLYN IN NEW YORK CITY (NYC). () - May 4, 2020 - Abstract #DDW2020DDW_4686;
1) The expansion of screening for C-HCV beyond baby boomers is paramount in its eradication, 2) the suboptimal adherence to appointments may be a reflection of the high risk behaviors that exposed patients to C-HCV. Recommendations: the extension of hepatology services to primary care and behavioral health seem essential to improve access to care and cure of C-HCV
- ||| acyclovir / Generic mfg., Sovaldi (sofosbuvir) / Gilead
Getting a little tired of all these claims that antivirals « never work ». Ever heard of: - ART for HIV - Gancyclovir for CMV (and others) - Entacivir for hep B - Sofosbuvir for hep C (and others) - Acyclovir for HSV? ... ID folks please raise your voices! @PergamIC @LeahYoke (Twitter) - May 2, 2020
- | Copegus (ribavirin) / Bausch Health, Sovaldi (sofosbuvir) / Gilead
Journal: Antiviral candidates for treating hepatitis E virus infection. (Pubmed Central) - May 1, 2020
Sofosbuvir has previously exhibited mixed results against HEV as an antiviral, both in vitro and in a handful of clinical applications, however in this study it was effective against the HEV genotype 1 replicon (EC 1.97 μM, CC >100 μM) and reduced replicon RNA levels (47.2% reduction at 10 μM). Together these studies indicate drug repurposing may be a promising pathway for development of antivirals against HEV infection.
- || pibrentasvir (ABT-530) / AbbVie, glecaprevir (ABT-493) / AbbVie, voxilaprevir (GS-9857) / Gilead
Clinical, Journal: Retreatment of Hepatitis C Virus-Infected Patients with Direct-Acting Antiviral Failures. (Pubmed Central) - Apr 30, 2020
The triple combination of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks is the first-line retreatment strategy in patients previously exposed to DAAs. Difficult-to-retreat patients may benefit from the combination of sofosbuvir plus glecaprevir/pibrentasvir and/or the addition of ribavirin and/or longer retreatment duration.
- | Sovaldi (sofosbuvir) / Gilead
Journal: Impact of Sofosbuvir-Based Therapy on Liver Transplant Candidates with Hepatitis C Virus Infection. (Pubmed Central) - Apr 29, 2020
During the study period reflecting early sofosbuvir use, few liver transplant candidates received sofosbuvir. Use was associated with lower incidence of transplant and a trend toward more waitlist removals due to improved condition.
- || Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead
Trial completion date, Trial primary completion date: A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection (clinicaltrials.gov) - Apr 28, 2020
P=N/A, N=1609, Active, not recruiting, Sponsor: Gilead Sciences
Use was associated with lower incidence of transplant and a trend toward more waitlist removals due to improved condition. Trial completion date: Aug 2023 --> Jan 2023 | Trial primary completion date: Aug 2023 --> Jan 2023
- || Sovaldi (sofosbuvir) / Gilead
Clinical, Journal, Real-world evidence: Real-World Study on Sofosbuvir-based Therapies in Asian Americans With Chronic Hepatitis C. (Pubmed Central) - Apr 27, 2020
Trial completion date: Aug 2023 --> Jan 2023 | Trial primary completion date: Aug 2023 --> Jan 2023 In Asian Americans with CHC, SOF-based regimens were well tolerated without serious AEs and could achieve high SVR12 regardless of hepatitis C viral infection GT.
- | Sovaldi (sofosbuvir) / Gilead
Journal: Potential Use of Sofosbuvir in the Prophylaxis for Rabies. (Pubmed Central) - Apr 25, 2020
In Asian Americans with CHC, SOF-based regimens were well tolerated without serious AEs and could achieve high SVR12 regardless of hepatitis C viral infection GT. No abstract available
- || Daklinza (daclatasvir) / BMS, sofosbuvir/velpatasvir / Generic mfg., Sovaldi (sofosbuvir) / Gilead
Clinical, Journal, Real-World Evidence: Real-world Effectiveness of Daclatasvir plus Sofosbuvir and Velpatasvir/Sofosbuvir in Hepatitis C Genotype 2 and 3. (Pubmed Central) - Apr 24, 2020
In genotype 2 and 3 HCV-infected patients, DCV+SOF±RBV and VEL/SOF±RBV produced similar SVR rates within genotype, and regimen did not have a significant impact on odds of SVR. For genotype 3 patients, prior treatment-experience and advanced liver disease were significant predictors of reduced odds of SVR regardless of regimen.
- | Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
Clinical, Journal: Effects of Dual Sofosbuvir/Daclatasvir Therapy on Weight and Linear Growth in Adolescent Patients with Chronic Hepatitis C Virus Infection. (Pubmed Central) - Apr 24, 2020
Contrarily, a trend to increased appetite and insignificant weight gain was observed, but further larger studies are needed to confirm. See Video-Abstract, http://links.lww.com/ASAIO/A381.
- || Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta
Clinical, Journal: Successful prolonged treatment of glecaprevir/pibrentasvir for chronic hepatitis C patient with treatment failure after 8-week therapy: a case report. (Pubmed Central) - Apr 22, 2020
Fortunately, a sustained virologic response was achieved without any adverse events. Although this was a single-case report and is assumed to be rare, the same regimen might be effective for treatment failure with 8-week GLE/PIB therapy.
- || Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
Clinical, Journal, Real-World Evidence: Sofosbuvir-based regimen for genotype 2 HCV infected patients in Taiwan: A real world experience. (Pubmed Central) - Apr 21, 2020
SOF/RBV, SOF/DCV or SOF/DCV/RBV for 12 weeks all achieve very high SVR rates and are equally effective in the treatment of genotype 2 CHC patients in the real world in Taiwan. Patients in the SOF/RBV group who have a history of HCC exhibit a lower SVR rate.
- || Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
Clinical, Journal: Use of sofosbuvir based regimen in patients with end-stage renal disease and chronic hepatitis C; an open label, non-randomized, single arm, single center study from Pakistan. (Pubmed Central) - Apr 21, 2020
The adverse effects were anemia in 58 (43.6 %) patients and elevated alanine transaminases in 11 (8.1%) patients. SOF in combination with either IFN or DAC is an equally efficacious and effective treatment regimen for patients on maintenance HD, especially in resource-poor countries.
- || Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
Clinical, Journal: Response And Tolerability Of Sofosbuvir Plus Daclatasvir In Elderly Patients With Chronic Hepatitis-C. (Pubmed Central) - Apr 17, 2020
SOF in combination with either IFN or DAC is an equally efficacious and effective treatment regimen for patients on maintenance HD, especially in resource-poor countries. Direct acting antiviral drug therapy is highly efficacious and safe for the treatment of HCV in older adults.
- | pibrentasvir (ABT-530) / AbbVie, glecaprevir (ABT-493) / AbbVie
Journal: Re-treatment of Hepatitis C Infection After Multiple Failures of Direct-Acting Antiviral Therapy. (Pubmed Central) - Apr 17, 2020
Multiple patient- and virus-related factors that do not affect cure rates in treatment-naive patients may need to be considered in choosing a re-treatment regimen for these patients. These regimens may need to include combinations drugs that are not available in single-tablet form, addition of ribavirin, and longer durations of treatment than standard.
- ||| Copegus (ribavirin) / Bausch Health, Sovaldi (sofosbuvir) / Gilead
Clinical, Journal, Adverse events: Fib-4 Predicts Early Hematological Adverse Events Induced by Interferon-Based Triple Therapy in Chronic Hepatitis C Virus Patients. (Pubmed Central) - Apr 16, 2020
A Fib-4 cutoff value of 3.59 had high specificity for anemia, leukopenia, and neutropenia (85.1%, 87.2%, and 88.2%, respectively), but had low sensitivity for detecting the 3 events. In conclusion, the Fib-4 score may predict early hematological adverse effects in HCV-infected patients on IFN-based triple therapy.
- || Sovaldi (sofosbuvir) / Gilead
Clinical, Journal: Pulmonary hypertension in patients with a history of intravenous drug use. (Pubmed Central) - Apr 16, 2020
In conclusion, the Fib-4 score may predict early hematological adverse effects in HCV-infected patients on IFN-based triple therapy. Eliciting a history of intravenous drug use is important and may be associated with a number of less common etiologies, each with specific diagnostic and therapeutic implications.
- | Sovaldi (sofosbuvir) / Gilead
PK/PD data, Journal: Synthesis and biological evaluation of deuterated sofosbuvir analogs as HCV NS5B inhibitors with enhanced pharmacokinetic properties. (Pubmed Central) - Apr 14, 2020
The Cmax and AUC of 40 in dogs were increased by 3.4 and 2.7 fold, respectively. Due to the enhanced pharmacokinetic properties and the great synthetic advantage of an inexpensive deuterium source (D O) for 40, it was chosen for further investigation.
- | Zepatier (grazoprevir/elbasvir) / Merck (MSD), Sovaldi (sofosbuvir) / Gilead, Cimivir-L (ledipasvir/sofosbuvir) / Gilead, Tehran University of Medical Sciences
Journal: Rescue Therapy for Genotype-3 DAA Non-responders, Almost all Done. (Pubmed Central) - Apr 14, 2020
All the cases achieved sustained virologic response (SVR) at week +12 without adverse effects. In our experience, this combo may represent an effective and safe option for these patients.
- || Sovaldi (sofosbuvir) / Gilead
Clinical, Journal: Liver stiffness measurements and FIB-4 are predictors of response to sofosbuvir-based treatment regimens in 7256 chronic HCV patients. (Pubmed Central) - Apr 14, 2020
Among different treatment protocol, patients with FIB-4 > 2.4, TE values >16.7 kPa are more prone to treatment failure except when using SOF/SIM treatment regimens. Baseline LS by TE and FIB-4 score may be useful for predicting treatment outcome in the new era of DAAs and could be integrated into pretreatment assessment of chronic HCV patients for better optimization of patient management.
- | remdesivir (GS-5734) / Gilead, Sovaldi (sofosbuvir) / Gilead
He's mixing up remdesivir and sovaldi, who knows, maybe on purpose, for the effect. (Twitter) - Apr 12, 2020
- || Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
Clinical, Journal: Treatment of chronic hepatitis C in patients with chronic kidney disease with Sofosbuvir-basead regimes. (Pubmed Central) - Apr 12, 2020
Sofosbuvir-based regimens are effective to treat HCV in patients with CKD. In patients with mild CKD this type of therapy seems to be safe.
- | Sovaldi (sofosbuvir) / Gilead
Journal: Modification of N,S co-doped graphene quantum dots with p-aminothiophenol-functionalized gold nanoparticles for molecular imprint-based voltammetric determination of the antiviral drug sofosbuvir. (Pubmed Central) - Apr 10, 2020
Graphical abstract Novel sofosbuvir imprinted p-ATP polymer was synthesized by the aid of gold nanoparticles on N,S co-doped graphene quantum dots as a good conductive support. The imprinted polymer was used for detection of sofosbuvir in real samples by using the ferri/ferrocyanide redox probe.
- | AT-527 / Atea Pharma, Sovaldi (sofosbuvir) / Gilead
Preclinical, Journal: Preclinical evaluation of AT-527, a novel guanosine nucleotide prodrug with potent, pan-genotypic activity against hepatitis C virus. (Pubmed Central) - Apr 10, 2020
When given orally to rats and monkeys, AT-527 preferentially delivered high levels of AT-9010 in the liver in vivo. These favorable preclinical attributes support the ongoing clinical development of AT-527 and suggest that, when used in combination with an HCV DAA from a different class, AT-527 may increase SVR rates, especially for difficult-to-treat patient populations, and could potentially shorten treatment duration for all patients.
- || Sovaldi (sofosbuvir) / Gilead
Clinical, Journal: Safety and Efficacy of Limited Laboratory Monitoring for Hepatitis C Treatment: A Blinded Clinical Trial in Rwanda. (Pubmed Central) - Apr 9, 2020
On-treatment laboratory monitoring did not improve patient outcomes in those treated with ledispasvir/sofosbuvir. Eliminating this monitoring in treatment programs in resource-limited settings may facilitate and accelerate scale-up of HCV therapy.
- | Sovaldi (sofosbuvir) / Gilead
Trial completion: Macrophage Activation Markers During Sofosbuvir-based Treatment Regimes of Chronic Hepatitis C (clinicaltrials.gov) - Apr 7, 2020
P=N/A, N=71, Completed, Sponsor: University of Aarhus
Eliminating this monitoring in treatment programs in resource-limited settings may facilitate and accelerate scale-up of HCV therapy. Active, not recruiting --> Completed
- || Sovaldi (sofosbuvir) / Gilead
Video: I had the honor of doing a video and being a guest speaker in 2015 after being cured of Hep C with Sovaldi . #gileadsavedmylife (Twitter) - Apr 5, 2020
- | Sovaldi (sofosbuvir) / Gilead
Clinical, Journal, Real-World Evidence: Serum Alpha-fetoprotein Levels and Response to Direct Antiviral Therapy in Patients with Chronic Hepatitis C: real-world results from 1716 patients in Egypt. (Pubmed Central) - Mar 31, 2020
Active, not recruiting --> Completed Serum AFP levels were a predictor for response in patients with chronic HCV with the administration of direct antiviral drugs.